• 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest
• 24-Hour Urine Collection
• 4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3
• A Direct Link Implicating Loss of SLC26A6 to Gut Microbial Dysbiosis, Compromised Barrier Integrity and Inflammation
• A Direct Link Implicating Loss of SLC26A6 to Gut Microbial Dysbiosis, Compromised Barrier Integrity, and Inflammation
• A molecular journey on the pathogenesis of primary hyperoxaluria
• A plain abdominal x-ray may direct the diagnosis of primary hyperoxaluria
• Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly
• Acute Renal Colic
• Bone health in children with primary hyperoxaluria type 1 following liver and kidney transplantation
• Bone Marrow Oxalosis
• Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive mendelian disorders using exome sequencing data in 1,642 Thais
• Case Report: effect of lumasiran treatment in a late preterm baby with antenatal diagnosis of primary hyperoxaluria type 1
• Circulating Oxalate Levels in Short Bowel Syndrome as a Severity Marker of CKD
• Clinical analysis of seven cases of primary hyperoxaluria type 1
• Clinical features and mutational spectrum of Chinese patients with primary hyperoxaluria type 2
• Clinicopathologic Characteristics, Etiologies, and Outcome of Secondary Oxalate Nephropathy
• Comprehensive evaluation of patients with primary hyperoxaluria type 1: A nationwide study
• Contrasting Response of Urine Stone Risk to Medical Treatment in Calcium Oxalate versus Calcium Phosphate Stone Formers
• Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1
• Current Dietary and Medical Prevention of Renal Calcium Oxalate Stones
• Delayed Graft Function After Kidney Transplantation: The Role of Residual Diuresis and Waste Products, as Oxalic Acid and Its Precursors
• Determinants and impact of calcium oxalate crystal deposition on renal outcomes in acute kidney injury patients
• Diagnosis and management of primary hyperoxalurias: best practices
• Effect of magnesium oxide or citrate supplements on metabolic risk factors in kidney stone formers with idiopathic hyperoxaluria: a randomized clinical trial
• Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
• Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
• Ethanolic extract of cotinuscoggygria leaves attenuates crystalluria and kidney damage in ethylene glycol-induced urolithiasis in rats
• Expanding the Genetic Spectrum of AGXT Gene Variants in Egyptian Patients with Primary Hyperoxaluria Type I
• Gene editing: a near future for the treatment of genetic kidney diseases
• Genetic kidney stones disease in adults
• Glycolate oxidase-1 gene variants influence the risk of hyperoxaluria and renal stone development
• Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylate
• Herbo-Mineral Medicine, Lithom Exhibits Anti-Nephrolithiasis Activity in Rat Model of Hyperoxaluria by Attenuating Calcium Oxalate Crystal Formation and Oxidative Stress
• Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis
• Histone deacetylase 6 suppression of renal tubular epithelial cell promotes interstitial mineral deposition via alpha-tubulin acetylation
• How We Treat Primary Hyperoxaluria Type 1
• Hyperoxaluria
• Impact of low-oxalate diet on hyperoxaluria among patients suffering from nephrolithiasis
• Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants
• Intestinal Oxalate Absorption, Enteric Hyperoxaluria, and Risk of Urinary Stone Formation in Patients with Crohn's Disease
• Kidney involvement in rare hereditary diseases
• Late Presentation of Primary Oxalosis, Microcrystalline Arthropathy, and Tumoral Calcinosis: A Case Report and a Literature Review
• Long-Term Sodium Deficiency Reduces Sodium Excretion but Impairs Renal Function and Increases Stone Formation in Hyperoxaluric Calcium Oxalate Rats
• Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy
• Lumasiran: A Review in Primary Hyperoxaluria Type 1
• Luminescence-based complementation assay to assess target engagement and cell permeability of glycolate oxidase (HAO1) inhibitors
• Management of urinary stones: state of the art and future perspectives by experts in stone disease
• Modified by the Innovative Drugs and Strategies-Pattern of Selected Indications for Pediatric Liver Transplantation
• Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1
• Multimodal Imaging Findings Associated With Cardiac Oxalosis Cardiomyopathy
• Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions
• Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status
• N-acetylcysteine regulates oxalate induced injury of renal tubular epithelial cells through CDKN2B/TGF-β/SMAD axis
• Nanoparticles and siRNA: A new era in therapeutics?
• Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs
• Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1
• Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3
• Nephrocalcinosis can disappear in infants receiving early lumasiran therapy
• Nephrology picture: metabolic acidosis with acute tubular injury-a noteworthy case
• Oxalate nephropathy after pancreaticoduodenectomy: a case report
• Oxalate nephropathy and chronic turmeric supplementation: a case report
• Oxalate nephropathy and chronic turmeric supplementation: a case report
• Oxalate Nephropathy: A Case Report of Acute Kidney Injury Due to Juice Diet
• Oxalates: Dietary Oxalates and Kidney Inflammation: A Literature Review
• Palmar papules as a manifestation of cutaneous oxalosis in primary hyperoxaluria: A case report and review of the literature
• Pathophysiology and management of enteric hyperoxaluria
• Pathophysiology and management of enteric hyperoxaluria
• Personalized Medicine in Urolithiasis: AI Chatbot-Assisted Dietary Management of Oxalate for Kidney Stone Prevention
• Plant-based therapies for urolithiasis: a systematic review of clinical and preclinical studies
• Porous Se@SiO(2) nanocomposites play a potential inhibition role in hyperoxaluria associated kidney stone by exerting antioxidant effects
• Prevalence and characteristics of genetic disease in adult kidney stone formers
• Primary hyperoxaluria detected by bone marrow biopsy: A case report
• Primary hyperoxaluria in adults and children: a nationwide cohort highlights a persistent diagnostic delay
• Primary hyperoxaluria type 1-a rare hereditary metabolic disorder as cause of livedo racemosa
• Primary hyperoxaluria type 1: Clinical, genetic, and evolutionary characteristics in Tunisian children
• Primary hyperoxaluria: Description of a new oral finding and review of literature
• Primary hyperoxaluria: Long-term outcomes of isolated kidney versus simultaneous liver/kidney transplant
• Recent Advances of Oxalate Decarboxylase: Biochemical Characteristics, Catalysis Mechanisms, and Gene Expression and Regulation
• Recurrent disease after pediatric renal transplantation
• Recurrent symptomatic urolithiasis in a patient with cystic fibrosis
• Resolution of Crystalline Retinopathy After Kidney Transplant for Hyperoxaluria
• Restored glyoxylate metabolism after AGXT gene correction and direct reprogramming of primary hyperoxaluria type 1 fibroblasts
• Review of childhood genetic nephrolithiasis and nephrocalcinosis
• Risk factors for recurrence in pediatric urinary stone disease
• RNA therapeutics for disorders of excretory system
• RNA therapeutics for metabolic disorders
• Simultaneous Liver Kidney Transplantation in a Primary Type 2 Hyperoxaluria With Corrected TOF and Severe Cardiomyopathy: A Case Report
• Small Interfering RNA (siRNA) Therapy
• Substituted 4-methylcoumarin inhibitors of SLC26A3 (DRA) for treatment of constipation and hyperoxaluria
• Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization
• The effect of <em>Myrtus communis</em> L. extract on nephrolithiasis model in rats
• The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria
• The protective effect of caffeine against oxalate-induced epithelial-mesenchymal transition in renal tubular cells via mitochondrial preservation
• The Yield of Genetic Testing in Management of Nephrolithiasis
• Unilateral Crystalline Ischemic Retinopathy Secondary to Primary Hyperoxaluria with Renal Failure and Oxalosis
• Unity Is Strength: The Mutual Alliance between CFTR and SLC26A6 as Therapeutic Opportunity in Cystic Fibrosis
• Unveiling atypical diagnoses: when whole-genome analysis performed for refractory infantile hypomagnesemia reveals primary hyperoxaluria
• Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases
• Urolithiasis in children; The importance of stone localization in treatment and follow-up